Prospective carriers of 223Ra for targeted alpha particle therapy

We report here on basic aspects that have to be addressed in TAT systems and describe our experiments with prospective carriers of Ra-223 intended for bone therapy based on hydroxyapatite nanoparticles. Preparation, in vitro stability tests are described. Labelling yields were ranging between 60-99 % depending on the reaction conditions. Preliminary static stability tests of successfully Ra-223-labelled hydroxyapatite nanoparticles were performed in a physiological saline and showed relatively low activity washout within 24 h (<5 % of total sample activity).